Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
Sean Dickson, Nico Gabriel, Inmaculada Hernandez
Abstract
We estimated list and net prices for tenofovir disoproxil fumarate (TDF) products Truvada, Complera, and Stribild, and their tenofovir alafenamide (TAF) versions Descovy, Odefsey, and Genvoya. Gilead offered discounts for Descovy that resulted into lower net prices compared to Truvada. This strategy encouraged patients switching from Truvada to Descovy before the availability of generic Truvada. Conversely, Gilead offered lower discounts for Odefsey and Genvoya, which resulted into higher net prices compared to Complera and Stribild.
Topics & Concepts
Tenofovir alafenamideTenofovirHuman immunodeficiency virus (HIV)EmtricitabineVirologyMedicineViral loadAntiretroviral therapyHIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentPharmaceutical Economics and Policy